2022
DOI: 10.1186/s12864-022-08825-w
|View full text |Cite
|
Sign up to set email alerts
|

Performance comparison of Agilent new SureSelect All Exon v8 probes with v7 probes for exome sequencing

Abstract: Exome sequencing is becoming a routine in health care, because it increases the chance of pinpointing the genetic cause of an individual patient's condition and thus making an accurate diagnosis. It is important for facilities providing genetic services to keep track of changes in the technology of exome capture in order to maximize throughput while reducing cost per sample. In this study, we focused on comparing the newly released exome probe set Agilent SureSelect Human All Exon v8 and the previous probe set… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 19 publications
0
2
0
Order By: Relevance
“…Various studies have evaluated the effectiveness of established enrichment technologies such as Agilent SureSelect, Nimblegen SeqCap and Illumina TruSeq [ 8 10 , 23 26 ]. These comparisons have shown relatively modest differences between the most recent versions of these technologies, mostly due to differences in target design.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Various studies have evaluated the effectiveness of established enrichment technologies such as Agilent SureSelect, Nimblegen SeqCap and Illumina TruSeq [ 8 10 , 23 26 ]. These comparisons have shown relatively modest differences between the most recent versions of these technologies, mostly due to differences in target design.…”
Section: Methodsmentioning
confidence: 99%
“…These characteristics may give rise to differences in the overall coverage uniformity and capture efficiency of specific targets, resulting in decreased variant calling sensitivity. Several studies that compared exome capture technologies have shown that there are major differences in their performance [ 7 10 ] and that high average read depth does not guarantee coverage for individual targets. In these comparative studies, extreme GC content [ 11 13 ] and mappability issues [ 12 , 14 ] are shown to be the major sources of coverage bias.…”
Section: Introductionmentioning
confidence: 99%